Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Laminin subunit beta-3 (LAMB3) is a structural protein encoded by the LAMB3 gene, serving as the beta chain of laminin-332, a major component of the basement membrane underlying epithelial tissues such as skin. Laminin-332 (formerly laminin-5), composed of alpha-3, beta-3, and gamma-2 chains, is essential for cell adhesion, migration, and the formation of the anchoring filaments that stabilize the epidermal-dermal junction. LAMB3 plays critical roles in the maintenance and repair of epithelial barriers, wound healing, and organ morphogenesis. Mutations in LAMB3 cause junctional epidermolysis bullosa, a severe inherited disorder characterized by skin fragility and blister formation. Aberrant expression is linked to malignant progression and poor prognosis in several cancer types, and is being investigated as a prognostic biomarker and potential therapeutic target in oncology and inflammatory diseases[1][3][4][7][8][10].
Not established for direct drug targeting; experimental/therapeutic strategies may affect laminin–integrin interactions, cell adhesion, and migration via antibodies or small molecules, but these are not approved.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Laminin subunit beta-3 (LAMB3).